Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

12.1%

8 terminated/withdrawn out of 66 trials

Success Rate

86.7%

+0.2% vs industry average

Late-Stage Pipeline

21%

14 trials in Phase 3/4

Results Transparency

87%

45 of 52 completed trials have results

Key Signals

2 recruiting45 with results6 terminated

Enrollment Performance

Analytics

Phase 1
18(29.0%)
Phase 2
18(29.0%)
Phase 3
8(12.9%)
Phase 4
6(9.7%)
Early Phase 1
6(9.7%)
N/A
6(9.7%)
62Total
Phase 1(18)
Phase 2(18)
Phase 3(8)
Phase 4(6)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (66)

Showing 20 of 66 trials
NCT01760005Phase 2Active Not Recruiting

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

Role: collaborator

NCT03143374Phase 2Recruiting

PET Tau - Neurodegenerative Disease Imaging

Role: collaborator

NCT02350634Phase 1Completed

18F-AV-1451 High Resolution Autopsy Study

Role: lead

NCT01606488Phase 4Active Not Recruiting

Effects of Brain Beta-Amyloid on Postoperative Cognition

Role: collaborator

NCT03019757Recruiting

Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease

Role: collaborator

NCT01447719Phase 3Completed

Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07

Role: lead

NCT02850146Phase 1Completed

18F-AV-1451 PET Imaging in Participants Enrolled in the LEARN Study

Role: collaborator

NCT02958670Not ApplicableActive Not Recruiting

Imaging Tau Deposition in the Brain of Elderly Subjects

Role: collaborator

NCT05775601Early Phase 1Completed

18F-LY3950321-01 Biodistribution and Safety Study

Role: lead

NCT04623242Phase 2Completed

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.

Role: collaborator

NCT01565382Phase 3Completed

Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)

Role: lead

NCT04721756Early Phase 1Unknown

Early Clinical Evaluation of 18F-LY3546117 in Tumor Imaging

Role: lead

NCT02164643Phase 3Completed

Longitudinal Study of Brain Amyloid imaGing in MEMENTO

Role: collaborator

NCT03040427Phase 4Terminated

The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis

Role: collaborator

NCT02486250Completed

Online Neuropsychological Test Validation Project With Imaging Pilot

Role: collaborator

NCT04474405Early Phase 1Completed

Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired Subjects

Role: lead

NCT03052972Phase 1Terminated

Flortaucipir 18F PET Imaging in BIOCARD Study

Role: lead

NCT03040713Phase 1Completed

Flortaucipir PET Imaging in Subjects With FTD

Role: lead

NCT04468347Phase 1Completed

Flortaucipir PET Imaging in the Preclinical, Prodromal and Dementia Phases of Alzheimer's Disease

Role: lead

NCT02016560Phase 2Completed

Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects

Role: lead